Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome.

Boucher P, Li WP, Matz RL, Takayama Y, Auwerx J, Anderson RG, Herz J.

PLoS One. 2007 May 16;2(5):e448.

2.

LRP1 regulates architecture of the vascular wall by controlling PDGFRbeta-dependent phosphatidylinositol 3-kinase activation.

Zhou L, Takayama Y, Boucher P, Tallquist MD, Herz J.

PLoS One. 2009 Sep 9;4(9):e6922. doi: 10.1371/journal.pone.0006922.

3.

Macrophage LRP1 suppresses neo-intima formation during vascular remodeling by modulating the TGF-β signaling pathway.

Muratoglu SC, Belgrave S, Lillis AP, Migliorini M, Robinson S, Smith E, Zhang L, Strickland DK.

PLoS One. 2011;6(12):e28846. doi: 10.1371/journal.pone.0028846. Epub 2011 Dec 9.

5.

LRP: role in vascular wall integrity and protection from atherosclerosis.

Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J.

Science. 2003 Apr 11;300(5617):329-32.

6.

Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity.

Strickland DK, Au DT, Cunfer P, Muratoglu SC.

Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):487-98. doi: 10.1161/ATVBAHA.113.301924. Epub 2014 Feb 6. Review.

7.

Transforming growth factor β inhibits platelet derived growth factor-induced vascular smooth muscle cell proliferation via Akt-independent, Smad-mediated cyclin D1 downregulation.

Martin-Garrido A, Williams HC, Lee M, Seidel-Rogol B, Ci X, Dong JT, Lassègue B, Martín AS, Griendling KK.

PLoS One. 2013 Nov 13;8(11):e79657. doi: 10.1371/journal.pone.0079657. eCollection 2013.

8.

LRP1 protects the vasculature by regulating levels of connective tissue growth factor and HtrA1.

Muratoglu SC, Belgrave S, Hampton B, Migliorini M, Coksaygan T, Chen L, Mikhailenko I, Strickland DK.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2137-46. doi: 10.1161/ATVBAHA.113.301893. Epub 2013 Jul 18.

9.

Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome.

Crosas-Molist E, Meirelles T, López-Luque J, Serra-Peinado C, Selva J, Caja L, Gorbenko Del Blanco D, Uriarte JJ, Bertran E, Mendizábal Y, Hernández V, García-Calero C, Busnadiego O, Condom E, Toral D, Castellà M, Forteza A, Navajas D, Sarri E, Rodríguez-Pascual F, Dietz HC, Fabregat I, Egea G.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):960-72. doi: 10.1161/ATVBAHA.114.304412. Epub 2015 Jan 15.

10.

PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.

Zhang LL, Gao CY, Fang CQ, Wang YJ, Gao D, Yao GE, Xiang J, Wang JZ, Li JC.

Cardiovasc Res. 2011 Dec 1;92(3):484-93. doi: 10.1093/cvr/cvr238. Epub 2011 Aug 31.

PMID:
21880694
11.

Regional changes in elastic fiber organization and transforming growth factor β signaling in aortas from a mouse model of marfan syndrome.

Howell DW, Popovic N, Metz RP, Wilson E.

Cell Tissue Res. 2014 Dec;358(3):807-19. doi: 10.1007/s00441-014-1993-7. Epub 2014 Sep 20.

PMID:
25238995
12.

Low density lipoprotein receptor-related protein 1 modulates the proliferation and migration of human hepatic stellate cells.

Llorente-Cortes V, Barbarigo V, Badimon L.

J Cell Physiol. 2012 Oct;227(10):3528-33. doi: 10.1002/jcp.24080.

PMID:
22392894
13.

[PPARγ up-regulates TGFβ/smad signal pathway repressor c-Ski].

Li GB, Li J, Zeng YJ, Zhong D, Wu GZ, Fu XH, He FT, Dai SS.

Sheng Li Xue Bao. 2011 Feb 25;63(1):62-8. Chinese.

14.

PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.

Yang HM, Kim BK, Kim JY, Kwon YW, Jin S, Lee JE, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS.

Exp Mol Med. 2013 Nov 29;45:e65. doi: 10.1038/emm.2013.112.

15.

Smooth muscle cell deletion of low-density lipoprotein receptor-related protein 1 augments angiotensin II-induced superior mesenteric arterial and ascending aortic aneurysms.

Davis FM, Rateri DL, Balakrishnan A, Howatt DA, Strickland DK, Muratoglu SC, Haggerty CM, Fornwalt BK, Cassis LA, Daugherty A.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):155-62. doi: 10.1161/ATVBAHA.114.304683. Epub 2014 Nov 13.

16.

Smooth muscle LDL receptor-related protein-1 deletion induces aortic insufficiency and promotes vascular cardiomyopathy in mice.

Basford JE, Koch S, Anjak A, Singh VP, Krause EG, Robbins N, Weintraub NL, Hui DY, Rubinstein J.

PLoS One. 2013 Nov 29;8(11):e82026. doi: 10.1371/journal.pone.0082026. eCollection 2013.

17.

Inhibitory effect of dehydrozingerone on vascular smooth muscle cell function.

Liu Y, Dolence J, Ren J, Rao M, Sreejayan N.

J Cardiovasc Pharmacol. 2008 Nov;52(5):422-9. doi: 10.1097/FJC.0b013e31818aed93.

PMID:
19033821
18.

Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.

Fred RG, Boddeti SK, Lundberg M, Welsh N.

Clin Sci (Lond). 2015 Jan;128(1):17-28. doi: 10.1042/CS20130560.

PMID:
24865476
19.

[Expression of early growth response gene-1 and its correlative genes in autogenous vein graft and significance thereof: an experiment with rats].

Liu CW, Hu XH, Yang J, Zhang Q, Zhang XS, Duan ZQ.

Zhonghua Yi Xue Za Zhi. 2005 Dec 21;85(48):3414-8. Chinese.

PMID:
16409863
20.

Cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation.

LeClair RJ, Durmus T, Wang Q, Pyagay P, Terzic A, Lindner V.

Circ Res. 2007 Mar 30;100(6):826-33. Epub 2007 Feb 22. Erratum in: Circ Res. 2012 May 11;110(10):e72.

Supplemental Content

Support Center